Clinical trial
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory…
NCT00085150 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00085150 |
|---|---|
| Title | LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma |
| Official title | Pediatric Phase I Trial of LMB-2 for Refractory CD25-Positive Leukemias and Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Biological |
| Interventions | LMB-2 immunotoxin |
| Enrollment | 40 |
| Start date | Apr 1, 2004 |
| First posted | Jun 11, 2004 |
| Last update posted | Apr 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: